$BGNE BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

on June 11, 2021 News and Tags: , , , with 0 comments
Time:
3:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

on June 11, 2021 News and Tags: , , , with 0 comments
Time:
3:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies

on June 9, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

on May 19, 2021 News and Tags: , , , with 0 comments
Time:
5:00 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

on May 19, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress

on May 12, 2021 News and Tags: , , , with 0 comments
Time:
10:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

on May 7, 2021 News and Tags: , , , with 0 comments
Time:
12:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

on May 6, 2021 News and Tags: , , , with 0 comments
Time:
12:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Reports First Quarter 2021 Financial Results

on May 6, 2021 News and Tags: , , , with 0 comments
Time:
4:05 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against

on April 28, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021

on April 12, 2021 News and Tags: , , , with 0 comments
Time:
1:30 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

on April 11, 2021 News and Tags: , , , with 0 comments
Time:
4:00 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress

on April 8, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China

on April 7, 2021 News and Tags: , , , with 0 comments
Time:
7:00 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021

on March 10, 2021 News and Tags: , , , with 0 comments
Time:
4:30 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan

on February 26, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results

on February 25, 2021 News and Tags: , , , with 0 comments
Time:
4:05 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

on February 17, 2021 News and Tags: , , , with 0 comments
Time:
5:00 PM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more

$BGNE BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia

on February 17, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
BGNE
Source:
Business Wire News Releases
Read more